Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05082025
Title	Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	endometrial cancer ovarian cancer breast cancer Advanced Solid Tumor
Therapies	Copanlisib + Fulvestrant
Age Groups:	adult \| senior
Covered Countries	USA